User login
Key clinical point: Atypical hyperplasia (AH) at the surgical margins of breast-conserving surgery (BCS) did not increase the risk for ipsilateral breast cancer (BC) recurrence, distant metastasis, or mortality in patients with BC who had received neoadjuvant chemotherapy (NAC).
Major finding: The 5-year ipsilateral breast tumor recurrence (IBTR) rate was 4.6% (95% CI 3.2%-6.0%) in patients with AH and 6.2% (95% CI 4.6%-7.8%) in patients without AH, with no significant differences observed between both groups in terms of IBTR (P = .448), distant metastasis-free survival (P = .506), and overall survival (P = .432).
Study details: Findings are from a retrospective analysis including 598 patients with BC who received NAC and BCS, of which 301 patients had AH at the margins of BCS and 297 patients did not have AH at the margins of BCS.
Disclosures: This study was supported by grants from the Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Su A et al. Impact of atypical hyperplasia at surgical margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy. Front Oncol. 2023;13:1202689 (May 19). Doi: 10.3389/fonc.2023.1202689
Key clinical point: Atypical hyperplasia (AH) at the surgical margins of breast-conserving surgery (BCS) did not increase the risk for ipsilateral breast cancer (BC) recurrence, distant metastasis, or mortality in patients with BC who had received neoadjuvant chemotherapy (NAC).
Major finding: The 5-year ipsilateral breast tumor recurrence (IBTR) rate was 4.6% (95% CI 3.2%-6.0%) in patients with AH and 6.2% (95% CI 4.6%-7.8%) in patients without AH, with no significant differences observed between both groups in terms of IBTR (P = .448), distant metastasis-free survival (P = .506), and overall survival (P = .432).
Study details: Findings are from a retrospective analysis including 598 patients with BC who received NAC and BCS, of which 301 patients had AH at the margins of BCS and 297 patients did not have AH at the margins of BCS.
Disclosures: This study was supported by grants from the Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Su A et al. Impact of atypical hyperplasia at surgical margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy. Front Oncol. 2023;13:1202689 (May 19). Doi: 10.3389/fonc.2023.1202689
Key clinical point: Atypical hyperplasia (AH) at the surgical margins of breast-conserving surgery (BCS) did not increase the risk for ipsilateral breast cancer (BC) recurrence, distant metastasis, or mortality in patients with BC who had received neoadjuvant chemotherapy (NAC).
Major finding: The 5-year ipsilateral breast tumor recurrence (IBTR) rate was 4.6% (95% CI 3.2%-6.0%) in patients with AH and 6.2% (95% CI 4.6%-7.8%) in patients without AH, with no significant differences observed between both groups in terms of IBTR (P = .448), distant metastasis-free survival (P = .506), and overall survival (P = .432).
Study details: Findings are from a retrospective analysis including 598 patients with BC who received NAC and BCS, of which 301 patients had AH at the margins of BCS and 297 patients did not have AH at the margins of BCS.
Disclosures: This study was supported by grants from the Natural Science Foundation of China. The authors declared no conflicts of interest.
Source: Su A et al. Impact of atypical hyperplasia at surgical margins on breast cancer outcomes in patients treated with neoadjuvant chemotherapy. Front Oncol. 2023;13:1202689 (May 19). Doi: 10.3389/fonc.2023.1202689